$APYP
APPYEA, INC Stock $apyp

$apyp Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031239 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$1.000K	$2.000K	$0.00
YoY Change
Cost Of Revenue	$2.000K	$3.000K
YoY Change
Gross Profit	-$1.000K	-$1.000K
YoY Change
Gross Profit Margin	-100.0%	-50.0%
Selling, General & Admin	$451.0K	$308.0K	$442.0K
YoY Change	46.43%	-30.32%	-30.39%
% of Gross Profit
Research & Development	$159.0K	$96.00K	$7.000K
YoY Change	367.65%	1271.43%	-58.82%
% of Gross Profit
Depreciation & Amortization		$6.000K	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$610.0K	$404.0K	$449.0K
YoY Change	78.36%	-10.02%	-31.13%
Operating Profit	-$610.0K	-$405.0K	-$449.0K
YoY Change	78.36%	-9.8%	-31.13%
Interest Expense		-$130.0K	$10.00K
YoY Change		-1400.0%	-133.33%
% of Operating Profit
Other Income/Expense, Net		-$130.0K	$12.00K
YoY Change		-1183.33%	-140.0%
Pretax Income	-$512.0K	$181.0K	-$342.0K
YoY Change	-64.84%	-152.92%	-57.62%
Income Tax
% Of Pretax Income
Net Earnings	-$512.0K	$181.0K	-$342.0K
YoY Change	-64.84%	-152.92%	-57.62%
Net Earnings / Revenue	-51200.0%	9050.0%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share		$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	475.2M shares	451.1M shares	229.6M shares
Diluted Shares Outstanding	483.9M shares	453.5M shares	234.9M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$158.0K	$50.00K
YoY Change		216.0%	-73.68%
Cash & Equivalents	$56.00K	$158.0K	$47.00K
Short-Term Investments
Other Short-Term Assets		$9.000K
YoY Change
Inventory	$13.00K	$13.00K
Prepaid Expenses
Receivables		$17.00K	$40.00K
Other Receivables	$18.00K	$17.00K	$43.00K
Total Short-Term Assets	$87.00K	$197.0K	$90.00K
YoY Change	-56.5%	118.89%	-74.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.000K	$2.000K	$1.000K
YoY Change	50.0%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$260.0K	$262.0K	$114.0K
YoY Change	80.56%	129.82%	-18.57%
TOTAL ASSETS
Total Short-Term Assets	$87.00K	$197.0K	$90.00K
Total Long-Term Assets	$260.0K	$262.0K	$114.0K
Total Assets	$347.0K	$459.0K	$204.0K
YoY Change	0.87%	125.0%	-58.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$22.00K	$40.00K
YoY Change		-45.0%	-33.33%
Accrued Expenses		$291.0K	$510.0K
YoY Change		-42.94%	200.0%
Deferred Revenue
YoY Change
Short-Term Debt	$79.00K	$78.00K	$233.0K
YoY Change	-90.8%	-66.52%	-63.59%
Long-Term Debt Due		$1.398M	$1.420M
YoY Change		-1.55%	4.41%
Total Short-Term Liabilities		$2.615M	$2.550M
YoY Change		2.55%	8.05%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.615M	$2.550M
Total Long-Term Liabilities		$0.00	$0.00
Total Liabilities	$2.527M	$2.615M	$2.546M
YoY Change	-30.33%	2.71%	8.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.901M	-$7.389M	-$5.140M
YoY Change	19.78%	43.75%
Common Stock	$47.00K	$45.00K	$22.00K
YoY Change	80.77%	104.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.166M	-$2.142M	-$2.328M
YoY Change
Total Liabilities & Shareholders Equity	$347.0K	$459.0K	$204.0K
YoY Change	0.87%	125.0%	-58.37%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$512.0K	$181.0K	-$342.0K
YoY Change	-64.84%	-152.92%	-57.62%
Depreciation, Depletion And Amortization		$6.000K	$0.00
YoY Change			-100.0%
Cash From Operating Activities		-$185.0K	-$90.00K
YoY Change		105.56%	-77.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$28.00K
YoY Change
Cash From Investing Activities		-$28.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	40.00K
YoY Change		-100.0%	-89.74%
NET CHANGE
Cash From Operating Activities		-185.0K	-90.00K
Cash From Investing Activities		-28.00K
Cash From Financing Activities		0.000	40.00K
Net Change In Cash		-213.0K	-50.00K
YoY Change		326.0%	400.0%
FREE CASH FLOW
Cash From Operating Activities		-$185.0K	-$90.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55403
	dei	Entity Registrant Name EntityRegistrantName	APPYEA, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gan Yavne
	dei	Entity Address Country EntityAddressCountry	IL
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	674-3561
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1496846
	dei	Entity Address Address Line1 EntityAddressAddressLine1	16 Natan Alterman St
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	475203251	shares
CY2024Q2	us-gaap	Inventory Net InventoryNet	13000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	197000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	260000	usd
CY2024Q2	us-gaap	Assets Assets	459000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	22000	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	291000	usd
CY2024Q2	APYP	Convertible Amortized Cost Current ConvertibleAmortizedCostCurrent	826000	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1398000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2615000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2615000	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	45000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7389000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2142000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2156000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	459000	usd
CY2023Q4	us-gaap	Government Assistance Amount Cumulative Current GovernmentAssistanceAmountCumulativeCurrent		usd
CY2024Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q2	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	APYP	Stock Issued During Period Value Upon Conversion Of Preferred Stock StockIssuedDuringPeriodValueUponConversionOfPreferredStock		usd
	APYP	Stock Issued During Period Share Issuance From Of Stock Payable StockIssuedDuringPeriodShareIssuanceFromOfStockPayable		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2024Q2	APYP	Stock Issued During Period Share Issuance From Of Stock Payable StockIssuedDuringPeriodShareIssuanceFromOfStockPayable		usd
	APYP	Financial Expenses Net FinancialExpensesNet		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	APYP	Research And Development Expenses Capitalization ResearchAndDevelopmentExpensesCapitalization		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	APYP	Related Partied Debt Conversion To Option For Common Stock RelatedPartiedDebtConversionToOptionForCommonStock		usd
	us-gaap	Management Fee Expense ManagementFeeExpense		usd
	us-gaap	Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium		usd
	APYP	Conversion Of Convertible Loan ConversionOfConvertibleLoan		usd
	APYP	Decrease Of Notes Purchased DecreaseOfNotesPurchased		usd
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2022Q4	APYP	Convertible Amortized Cost ConvertibleAmortizedCost		usd
	APYP	Transition From Convertible Loans Measured At Fair Value To Measurement At Amortized Cost TransitionFromConvertibleLoansMeasuredAtFairValueToMeasurementAtAmortizedCost		usd
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature		usd
	APYP	Financial Expenses Related To Transition From Fair Value Measurement To Amortized Cost FinancialExpensesRelatedToTransitionFromFairValueMeasurementToAmortizedCost		usd
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	222000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	42000	usd
CY2024Q2	us-gaap	Government Assistance Amount Cumulative Current GovernmentAssistanceAmountCumulativeCurrent	9000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	14000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	278000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	193000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	262000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	196000	usd
CY2023Q4	us-gaap	Assets Assets	474000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	51000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	694000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	78000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	79000	usd
CY2023Q4	APYP	Convertible Amortized Cost Current ConvertibleAmortizedCostCurrent	796000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1203000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	204000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3027000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3027000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	31000	usd
CY2024Q2	APYP	Shares To Be Issued SharesToBeIssued	333000	usd
CY2023Q4	APYP	Shares To Be Issued SharesToBeIssued	559000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4869000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3197000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6326000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2539000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2553000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	474000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	3000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	-1000	usd
	us-gaap	Gross Profit GrossProfit	9000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	156000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	103000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	157000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	205000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	440000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	499000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	867000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-405000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-449000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-803000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-885000	usd
CY2024Q2	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	716000	usd
CY2023Q2	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	95000	usd
	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	-108000	usd
	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	261000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-130000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-152000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7000	usd
	us-gaap	Profit Loss ProfitLoss	-1063000	usd
	us-gaap	Profit Loss ProfitLoss	-631000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-631000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	453450254	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	453450254	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2553000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	383000	usd
	APYP	Stock To Be Issued During Period Value Issued For Services StockToBeIssuedDuringPeriodValueIssuedForServices	25000	usd
	APYP	Stock To Be Issued During Period Value Issued To Investors StockToBeIssuedDuringPeriodValueIssuedToInvestors	75000	usd
	APYP	Shares To Be Issued Upon Warrant Exercise SharesToBeIssuedUponWarrantExercise	118000	usd
	APYP	Shares To Be Issued During Period Value SharesToBeIssuedDuringPeriodValue	14000	usd
	APYP	Stock Issued During Period Shares Issuance Upon Conversion Of Debt To Related Party StockIssuedDuringPeriodSharesIssuanceUponConversionOfDebtToRelatedParty	338000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	118000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	389000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1063000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2156000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	243000	usd
	APYP	Shares To Be Issued During Period Value SharesToBeIssuedDuringPeriodValue	47000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	562000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-631000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2342000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3167000	usd
CY2024Q2	APYP	Shares To Be Issued During Period Value SharesToBeIssuedDuringPeriodValue	14000	usd
CY2024Q2	APYP	Shares To Be Issued Upon Warrant Exercise SharesToBeIssuedUponWarrantExercise	118000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	118000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	242000	usd
CY2024Q2	APYP	Stock Issued During Period Shares Issuance Upon Conversion Of Debt To Related Party StockIssuedDuringPeriodSharesIssuanceUponConversionOfDebtToRelatedParty	338000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	181000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2156000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2411000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2411000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	83000	usd
CY2023Q2	APYP	Shares To Be Issued During Period Value SharesToBeIssuedDuringPeriodValue	46000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	282000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-342000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-342000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2342000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2342000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-631000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	430000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	570000	usd
	APYP	Financial Income Net Including Changes In Convertible Loans And Warrants FinancialIncomeNetIncludingChangesInConvertibleLoansAndWarrants	-108000	usd
	APYP	Financial Income Net Including Changes In Convertible Loans And Warrants FinancialIncomeNetIncludingChangesInConvertibleLoansAndWarrants	261000	usd
	APYP	Financial Expenses Net FinancialExpensesNet	152000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-16000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	24000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-53000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	76000	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-43000	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	66000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-442000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-192000	usd
	APYP	Research And Development Expenses Capitalization ResearchAndDevelopmentExpensesCapitalization	78000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	456000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	40000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	141000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	456000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-64000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	60000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	158000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51000	usd
	APYP	Related Partied Debt Conversion To Option For Common Stock RelatedPartiedDebtConversionToOptionForCommonStock	338000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_809_eus-gaap--NatureOfOperations_zNMrcC1plxJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_826_zx7pl5dTCtAa">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no significant operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX LTD is a company formed under the laws of the State of Israel and a wholly owned subsidiary of the Company (“SleepX”). SleepX is a research and development company that has developed a proprietary product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the Company started serial production in 2023. Subject to raising working capital, of which no assurance can be provided, the Company intends to focus on further development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operations. Since its incorporation and as of the financial statements date, Sleepx holds <span id="xdx_90B_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20240630__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zyPc8jW5ntg7" title="Voting interest rate">66.7</span>% of the voting interest of Ta-nooma.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic Development</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company flagship product is AppySleep – A Biofeedback snoring treatment wristband, combined with the AppySleep App (“AppySleep”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The AppySleep product is currently in serial manufacturing and commercial stage. The new AppySleep IOS and Android versions were launched during the third quarter of 2024. During the first 6 months of 2024 the company didn’t invest substantial capital in marketing AppySleep in order to invest it once the IOS version will be available for download, since the company saw significant demand in the US market for the AppySleep IOS version.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial position</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements are presented on a going-concern basis. To date, the Company has not generated any significant revenues, suffered recurring losses from operations, incurred negative cash flows from operating activities, and is dependent upon external sources for financing its operations. As of June 30, 2024, the Company had an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20240630_zAdV2MxtEaU6" title="Retained earnings accumulated deficit">7,389,000</span> and a stockholders’ deficiency of $<span id="xdx_908_eus-gaap--StockholdersEquity_iNI_pn3d_di_c20240630_z8JY4Ntv6kj6" title="Equity including portion attributable to noncontrolling interest">2,142,000</span>. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments for the values of assets and liabilities and their classification that may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPYEA INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7389000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2142000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zZ88s9lR98gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zzdcKoUH8oZ3">Use of Estimates in Preparation of Financial Statements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	59000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	498000	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	42000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	129000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	78000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	79000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	330000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	526000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	445000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	614000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	90000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1203000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	2257000	usd
CY2023	us-gaap	Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium	153000	usd
CY2023	APYP	Conversion Of Convertible Loan ConversionOfConvertibleLoan	-243000	usd
CY2023	APYP	Decrease Of Notes Purchased DecreaseOfNotesPurchased	-530000	usd
	APYP	Change In Fair Value Of Convertible Loans Liability Through Profit Or Loss ChangeInFairValueOfConvertibleLoansLiabilityThroughProfitOrLoss	-195000	usd
CY2023	APYP	Change In Fair Value Of Convertible Loans Liability Through Profit Or Loss ChangeInFairValueOfConvertibleLoansLiabilityThroughProfitOrLoss	434000	usd
CY2024Q2	us-gaap	Convertible Debt ConvertibleDebt	1398000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1203000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	152750	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	242538	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	8634616	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.0001
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	117580	usd
CY2023Q4	APYP	Convertible Amortized Cost ConvertibleAmortizedCost	796000	usd
CY2023	APYP	Transition From Convertible Loans Measured At Fair Value To Measurement At Amortized Cost TransitionFromConvertibleLoansMeasuredAtFairValueToMeasurementAtAmortizedCost	530000	usd
CY2023	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	66000	usd
CY2023	APYP	Financial Expenses Related To Transition From Fair Value Measurement To Amortized Cost FinancialExpensesRelatedToTransitionFromFairValueMeasurementToAmortizedCost	304000	usd
	APYP	Accrued Interest In Profit And Loss AccruedInterestInProfitAndLoss	30000	usd
CY2023	APYP	Accrued Interest In Profit And Loss AccruedInterestInProfitAndLoss	28000	usd
CY2024Q2	APYP	Convertible Amortized Cost ConvertibleAmortizedCost	826000	usd
CY2023Q4	APYP	Convertible Amortized Cost ConvertibleAmortizedCost	796000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1500000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	197966	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	APYP	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024Q2	APYP	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-031239-index-headers.html	Edgar Link	pending
0001493152-24-031239-index.html	Edgar Link	pending
0001493152-24-031239.txt	Edgar Link	pending
0001493152-24-031239-xbrl.zip	Edgar Link	pending
apyp-20240630.xsd	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
apyp-20240630_cal.xml	Edgar Link	unprocessable
apyp-20240630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
apyp-20240630_pre.xml	Edgar Link	unprocessable
apyp-20240630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYP
APPYEA, INC Stock $apyp

2024 Q3 Form 10-Q Financial Statement

#000149315224031239 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP APPYEA, INC Stock $apyp

2024 Q3 Form 10-Q Financial Statement

#000149315224031239 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP
APPYEA, INC Stock $apyp